Immune gene expression signatures associated clinical benefit from nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: An immune biomarker analysis of phase III SWOG LungMAP S1400I trial

被引：0

作者：

Duose, Dzifa Y. ^{[1
]}

Zhang, Jiexin ^{[1
]}

Redman, Mary ^{[2
]}

Zhang, Baili ^{[1
]}

Cerami, Ethan ^{[3
]}

Lindsay, James ^{[3
]}

Yu, Joyce ^{[3
]}

Biswas, Roshni ^{[3
]}

Van Nostrand, Stephen ^{[3
]}

Moravec, Radim ^{[4
]}

Luthra, Rajyalakshmi ^{[1
]}

Al-Atrash, Gheath ^{[1
]}

Kelly, Karen ^{[5
]}

Herbst, Roy ^{[6
]}

Wistuba, Ignacio ^{[1
]}

Gettinger, Scott ^{[6
]}

Bazhenova, Lyudmila ^{[7
]}

Lee, J. Jack ^{[1
]}

Zhang, Jianjun ^{[1
]}

Haymaker, Cara ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[3] Dana Farber Canc Inst, Boston, MA USA

[4] Natl Canc Inst, Bethesda, MD USA

[5] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA

[6] Yale Sch Med, New Haven, CT USA

[7] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1974

引用

页数：2

共 24 条

[1] Infiltration and spatial distribution of immune cells are associated clinical benefit from Nivolumab and Ipilimumab for previously treated patients with stage IV squamous cell lung cancer: an immune biomarker analysis of Phase III SWOG LungMAP S1400I trial
Parra, Edwin Roger
Zhang, Jiexin
Redman, Mary
Lazcano, Rossana
Mario, Piubelli
Fernandez, Caddie Laberiano
Krishna, Renganayaki K.
Zhang, Shanyu
Chen, Hong
Manyam, Ganiraju
Moravec, Radim
Cerami, Ethan
Lindsay, James
Yu, Joyce
Biswas, Roshni
Van Nostrand, Stephen
Duose, Dzifa Y.
Zhang, Jianjun
Herbst, Roy
Al-Atrash, Gheath
Kannan, Kasthuri
Wistuba, Ignacio I.
Gettinger, Scott
Bazhenova, Lyudmila
Lee, Jack
Zhang, Jianhua
Haymaker, Cara
CANCER RESEARCH, 2022, 82 (12)
[2] Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.
Parra, Edwin R.
Duose, Dzifa Yawa
Zhang, Jiexin
Redman, Mary Weber
Segura, Rossana Lazcano
Marques-Piubelli, Mario L.
Fernandez, Caddie Laberiano
Zhang, Baili
Lindsay, James
Moravec, Radim
Kannan, Kasthuri
Luthra, Rajyalakshmi
Alatrash, Gheath
Herbst, Roy S.
Wistuba, Ignacio Ivan
Gettinger, Scott N.
Bazhenova, Lyudmila
Lee, J. Jack
Zhang, Jianjun
Haymaker, Cara L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
Gettinger, Scott N.
Redman, Mary W.
Bazhenova, Lyudmila
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence H.
Bradley, Jeffrey D.
Stinchcombe, Thomas E.
Leighl, Natasha B.
Ramalingam, Suresh S.
Tavernier, Susan S.
Yu, Hui
Unger, Joseph M.
Minichiello, Katherine
Highleyman, Louise
Papadimitrakopoulou, Vassiliki A.
Kelly, Karen
Gandara, David R.
Herbst, Roy S.
JAMA ONCOLOGY, 2021, 7 (09) : 1368 - 1377
[4] A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).
Bazhenova, Lyudmila
Redman, Mary Weber
Gettinger, Scott N.
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence Howard
Gandara, David R.
Bradley, Jeffrey D.
Stinchcombe, Tom
Leighl, Natasha B.
Ramalingam, Suresh S.
Tavernier, Susan S.
Minichiello, Katherine
Kelly, Karen
Papadimitrakopoulou, Vassiliki
Herbst, Roy S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Parra, Edwin Roger
Zhang, Jiexin
Duose, Dzifa Yawa
Gonzalez-Kozlova, Edgar
Redman, Mary W.
Chen, Hong
Manyam, Ganiraju C.
Kumar, Gayatri
Zhang, Jianhua
Song, Xingzhi
Lazcano, Rossana
Marques-Piubelli, Mario L.
Laberiano-Fernandez, Caddie
Rojas, Frank
Zhang, Baili
Taing, Len
Jhaveri, Aashna
Geisberg, Jacob
Altreuter, Jennifer
Michor, Franziska
Provencher, James
Yu, Joyce
Cerami, Ethan
Moravec, Radim
Kannan, Kasthuri
Luthra, Rajyalakshmi
Alatrash, Gheath
Huang, Hsin-Hui
Xie, Hui
Patel, Manishkumar
Nie, Kai
Harris, Jocelyn
Argueta, Kimberly
Lindsay, James
Biswas, Roshni
Van Nostrand, Stephen
Kim-Schulze, Seunghee
Gray, Jhanelle E.
Herbst, Roy S.
Wistuba, Ignacio I.
Gettinger, Scott
Kelly, Karen
Bazhenova, Lyudmila
Gnjatic, Sacha
Lee, J. Jack
Zhang, Jianjun
Haymaker, Cara
CLINICAL CANCER RESEARCH, 2024, 30 (08) : 1655 - 1668
[6] Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.
Gonzalez-Kozlova, Edgar
Huang, Hsin-Hui
Redman, Mary Weber
Herbst, Roy S.
Gettinger, Scott N.
Bazhenova, Lyudmila
Xie, Hui
Patel, Manishkumar
Nie, Kai
Harris, Jocelyn
Argueta, Kimberly
Cerami, Ethan
Hong, Joyce
Biswas, Roshni
Van Nostrand, Stephen
Kelly, Karen
Moravec, Radim
Del Valle, Diane
Kim-Schulze, Seunghee
Gnjatic, Sacha
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer
Bazhenova, L.
Redman, M.
Gettinger, S.
Hirsch, F. R.
Mack, P.
Schwartz, L.
Gandara, D.
Bradley, J.
Stinchcombe, T.
Leighl, N.
Ramalingam, S.
Tavernier, S.
Minichiello, K.
Kelly, K.
Papadimitrakopoulou, V.
Herbst, R.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S214 - S214
[8] Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer
Gonzalez-Kozlova, Edgar
Huang, Hsin-Hui
Redman, Mary
Herbst, Roy
Gettinger, Scott
Bazhenova, Luda
Xie, Hui
Patel, Manishkumar
Nie, Kai
Harris, Jocelyn
Argueta, Kimberly
Kelly, Karen
Cerami, Ethan
Lindsay, James
Yu, Joyce
Biswas, Roshni
Van Nostrand, Stephen
Moravec, Radim
Del Valle, Diane Marie
Kim-schulze, Seunghee
Gnjatic, Sacha
CANCER RESEARCH, 2022, 82 (12)
[9] SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)
Borghaei, Hossein
Redman, Mary W.
Kelly, Karen
Waqar, Saima N.
Robert, Francisco
Kiefer, Gauri J.
Stella, Philip J.
Minichiello, Katherine
Gandara, David R.
Herbst, Roy S.
Papadimitrakopoulou, Vassiliki A.
CLINICAL LUNG CANCER, 2021, 22 (03) : 178 - 186
[10] A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub -study SWOG S1400C.
Edelman, Martin J.
Redman, Mary Weber
Albain, Kathy S.
McGary, Eric C.
Rafique, Norman
Petro, Daniel P.
Waqar, Saiama Naheed
Miao, Jieling
Griffin, Katie
Papadimitrakopoulou, Vassiliki
Kelly, Karen
Gandara, David R.
Herbst, Roy S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 →